Photo of Andy Chen, MD, PhD

Andy Chen MD, PhD

Dr. Chang's research focuses on understanding the biochemical mechanisms responsible for the genetic phenomenon known as DRT/DMC. Using both cytogenetic and biochemical techniques, he has been able to show a delay in protein recruitment to the chromosome. Dr. Chang's research continues to use these methods to further identify these mechanisms and their aberration within malignant cells. As a member of the stem cell transplant team, Dr. Chang hopes his research will further advance the treatment of this disease.

Education

  • Ph.D., Harvard University, Boston Massachusetts 0 2001
  • M.D., Harvard University, Boston Massachusetts 0 2001
  • Residency:

    • Internal medicine, Stanford University, 2004
  • Fellowship:

    • Hematology, medical oncology, and blood and marrow transplantation, Stanford University, 2008
  • Certifications:

    • American Board of Internal Medicine (hematology), 2008

Memberships and associations

  • American Society of Hematology

Publications

  • "Phase i study of the anti-CD22 antibody-drug conjugate pinatuzumab vedotin with/without rituximab in patients with relapsed/refractory B-cell non-hodgkin lymphoma." Clinical Cancer Research In: , Vol. 23, No. 5, 01.03.2017, p. 1167-1176.
  • "Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation." British Journal of Haematology  In: , Vol. 174, No. 2, 01.07.2016, p. 235-248.
  • "Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma : Comparison of a Multicenter Phase II Study and CIBMTR Outcomes." Biology of Blood and Marrow Transplantation In: , Vol. 22, No. 7, 01.07.2016, p. 1197-1205.
  • "Patient-reported outcomes of brentuximab vedotin in Hodgkin lymphoma and anaplastic large-cell lymphoma." OncoTargets and Therapy  In: , Vol. 9, 06.04.2016, p. 2027-2034.
  • "Long-term survival outcomes of reduced-intensity allogeneic or autologous transplantation in relapsed grade 3 follicular lymphoma." Bone Marrow Transplantation In: , Vol. 51, No. 1, 01.01.2016, p. 58-66.
  • "Quality of life results from a phase 3 study of brentuximab vedotin consolidation following autologous haematopoietic stem cell transplant for persons with Hodgkin lymphoma." British Journal of Haematology In: , 2016.
  • "A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma." Bone Marrow Transplantation In: , Vol. 50, No. 11, 01.11.2015, p. 1416-1423.
  • "Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes." Leukemia In: , Vol. 29, No. 7, 13.07.2015, p. 1578-1586.
  • "Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA) : A randomised, double-blind, placebo-controlled, phase 3 trial." The Lancet  In: , Vol. 385, No. 9980, 09.05.2015, p. 1853-1862.
  • "Early Failure of Frontline Rituximab-Containing Chemo-immunotherapy in Diffuse Large B Cell Lymphoma Does Not Predict Futility of Autologous Hematopoietic Cell Transplantation." Biology of Blood and Marrow Transplantation  In: , Vol. 20, No. 11, 01.11.2014, p. 1729-1736.
  • "Aberrations of MYC are a common event in B-cell prolymphocytic leukemia." American Journal of Clinical Pathology  In: , Vol. 142, No. 3, 01.09.2014, p. 347-354.
  • "Improved outcome with busulfan, melphalan and thiotepa conditioning in autologous hematopoietic stem cell transplant for relapsed/refractory Hodgkin lymphoma." Leukemia and Lymphoma In: , Vol. 55, No. 3, 03.2014, p. 583-587.
  • "Autologous haematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement." British Journal of Haematology In: , Vol. 162, No. 5, 09.2013, p. 648-656.
  • "Diffuse large B-cell lymphoma in adults aged 75 years and older : A single institution analysis of cause-specific survival and prognostic factors." Therapeutic Advances in Hematology  In: , Vol. 4, No. 6, 2013, p. 349-353.
  • "Clinical experience with a simple algorithm for plerixafor utilization in autologous stem cell mobilization." Bone Marrow Transplantation In: , Vol. 47, No. 12, 12.2012, p. 1526-1529.
  • "Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma." Bone Marrow Transplantation In: , Vol. 47, No. 4, 04.2012, p. 516-521.
  • "Pre-transplant evaluation."   Blood and Marrow Transplant Handbook: Comprehensive Guide for Patient Care. Springer New York, 2011. p. 27-37.
  • "Long-Term Results Of Autologous Hematopoietic Cell Transplantation For Peripheral T Cell Lymphoma : The Stanford Experience." Biology of Blood and Marrow Transplantation In: , Vol. 14, No. 7, 07.2008, p. 741-747.
  • "Beyond the guidelines in the treatment of peripheral T-cell lymphoma : New drug development." JNCCN Journal of the National Comprehensive Cancer Network In: , Vol. 6, No. 4, 04.2008, p. 428-435.
  • "Paradoxical Dampening of Anti-Islet Self-Reactivity but Promotion of Diabetes by OX40 Ligand." Journal of Immunology  In: , Vol. 171, No. 12, 15.12.2003, p. 6954-6960.
  • "Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients." Blood In: , Vol. 101, No. 9, 01.05.2003, p. 3741-3748.
  • "Costimulatory molecule OX40L is critical for both Th1 and Th2 responses in allergic inflammation." European Journal of Immunology In: , Vol. 32, No. 10, 10.2002, p. 2874-2880.
  • "Ox40-ligand has a critical costimulatory role in dendritic cell : T cell interactions." Immunity In: , Vol. 11, No. 6, 12.1999, p. 689-698.

Additional information

Edit profile